Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026.

The accepted poster, presented by Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center, covers safety and preliminary efficacy results in advanced SSTR2-expressing neuroendocrine tumors. The poster is Abstract No. 635 in the session "Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract" and will be shown on January 9, 2026 at two times: 11:30 am–1:00 pm PT and 5:00–6:00 pm PT. ASCO-GI will release full regular-abstract details on January 5, 2026.

News Market Reaction

+8.14%

12 alerts

+8.14% News Effect

+3.0% Peak in 1 hr 47 min

+$13M Valuation Impact

$178M Market Cap

0.5x Rel. Volume

On the day this news was published, CATX gained 8.14%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $178M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: January 8–10, 2026 Abstract number: 635 Session date: January 9, 2026 +3 more

6 metrics

Conference dates January 8–10, 2026 ASCO-GI Congress 2026 meeting window for the presentation

Abstract number 635 VMT-α-NET safety and preliminary efficacy poster identifier at ASCO-GI

Session date January 9, 2026 Poster session on cancers of the pancreas, small bowel, hepatobiliary tract

Session time 11:30 am–1:00 pm PT First scheduled viewing window for the VMT-α-NET poster

Session time (evening) 5:00–6:00 pm PT Second scheduled viewing window for the VMT-α-NET poster

Abstract details release January 5, 2026 ASCO-GI regular-abstract information release date

Market Reality Check

Price: $2.55 Vol: Volume 1,642,913 is 14% b...

normal vol

$2.55 Last Close

Volume Volume 1,642,913 is 14% below the 20-day average of 1,917,360. normal

Technical Shares at $2.70 are trading below the 200-day MA of $3.01, well under the $5.3881 52-week high.

Peers on Argus

Peers showed mixed moves, with CERS up 11.4% and others like OM and QSI down aro...

Peers showed mixed moves, with CERS up 11.4% and others like OM and QSI down around 2–3%, suggesting stock-specific rather than broad sector momentum for CATX.

Common Catalyst Another peer, TLSI, also highlighted a procedure-focused event, indicating ongoing interest in interventional and device-based cancer care updates.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	ASCO-GI acceptance	Positive	+8.1%	VMT-α-NET safety and preliminary efficacy poster accepted for ASCO-GI 2026.
Nov 20	Investor conferences	Neutral	-7.8%	Management participation in December investor conferences and one-on-one meetings.
Nov 10	Q3 2025 earnings	Neutral	+1.4%	Q3 2025 financials plus clinical updates for VMT-α-NET, VMT01, and PSV359.
Oct 31	November conferences	Neutral	+3.4%	Planned attendance and presentations at November 2025 healthcare conferences.
Oct 24	Earnings notice	Neutral	+3.8%	Announcement of timing for third quarter 2025 results and business update.

Pattern Detected

Recent headlines often relate to clinical data, earnings, and conferences, with most events followed by modest positive price reactions and one notable negative move on a conference-participation update.

Recent Company History

This announcement fits a pattern of Perspective Therapeutics using major meetings to showcase its radiopharmaceutical pipeline. In mid-October, the company highlighted interim [212Pb]VMT-α-NET data at ESMO 2025, followed by a Q3 update on Nov 10, 2025 that reported a net loss of $25.969M and cash of $174.1M. Multiple conference-participation releases in October and November preceded this ASCO-GI acceptance, underscoring continued visibility-building around VMT-α-NET and other programs ahead of more mature data readouts.

Market Pulse Summary

The stock moved +8.1% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +8.1% in the session following this news. A strong positive reaction aligns with prior enthusiasm around [212Pb]VMT-α-NET, which previously coincided with a +8.14% move on related data visibility. The ASCO-GI acceptance adds another high-profile venue for safety and preliminary efficacy results. However, past headlines such as December conference participation saw a -7.83% move, underscoring that sentiment can reverse quickly. Investors have also seen continued losses and significant R&D spending, which could temper the durability of any sharp upside.

Key Terms

radiopharmaceutical, neuroendocrine tumors, somatostatin receptor subtype 2, SSTR2, +1 more

5 terms

radiopharmaceutical medical

"a radiopharmaceutical development company pioneering advanced treatments for cancers"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

neuroendocrine tumors medical

"in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs)"

Neuroendocrine tumors are a type of abnormal growth that originates from cells responsible for releasing hormones into the bloodstream. These tumors can develop in various parts of the body and sometimes grow slowly or remain hidden for years. Their potential to affect hormone levels and spread makes them important for investors to monitor, especially as advancements in treatment may influence healthcare company performance.

somatostatin receptor subtype 2 medical

"advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors"

Somatostatin receptor subtype 2 is a specific protein found on certain cells in the body that binds to a hormone called somatostatin, which helps regulate processes like hormone release and cell growth. In medical research and drug development, targeting this receptor can lead to new treatments for diseases such as tumors, making it an area of interest for investors looking at biotech innovations. Its significance lies in its potential to enable more precise therapies and improve patient outcomes.

SSTR2 medical

"advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors"

sstr2 is a protein on the surface of some cells that acts like a lock for the hormone somatostatin and similar drugs; many neuroendocrine tumors have lots of these locks. For investors, sstr2 matters because tests and medicines that find or fit this lock — such as targeted imaging agents and therapies — can enable diagnosis, guide treatment decisions, and create commercial opportunities if they gain regulatory approval and clinical adoption.

poster presentation technical

"Session Type: Poster presentation Session Title: Cancers of the Pancreas"

A poster presentation is a visual display of information, often used to share research findings or ideas at conferences or meetings. It usually consists of a large printed poster that summarizes key points, allowing viewers to quickly understand the main message and ask questions. For investors, it highlights important developments or insights in a clear, accessible way, helping them stay informed about new opportunities or trends.

AI-generated analysis. Not financial advice.

SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [²¹²Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026 taking place from January 8 to 10, 2026 in San Francisco, CA as detailed below. ASCO-GI has announced that it will release further details for regular abstracts for the conference on January 5, 2026.

Presenter	Abstract Title	Presentation Details
Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center	Safety and preliminary efficacy results of [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs)	Abstract Number: 635 Session Type: Poster presentation Session Title: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Session Date: January 9, 2026 Session Time: 11:30 am – 1:00 pm; 5:00 -6:00 pm PT

About [²¹²Pb]VMT-α-NET
Perspective designed [²¹²Pb]VMT-α-NET to target and deliver ²¹²Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT). Updated interim data from the study, as of a data-cut off (DCO) date of September 12, 2025, were presented at the European Society of Medical Oncology (ESMO) Congress 2025, the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

As of that DCO, safety findings based on 55 patients who had received at least one treatment showed [²¹²Pb]VMT-α-NET continued to demonstrate a favorable safety profile, with no dose-limiting toxicities (DLTs), treatment-related discontinuations, or Grade 4 or 5 treatment-emergent adverse events (TEAEs) reported.

Anti-tumor activity based on all patients in Cohort 1 and half of the patients enrolled in Cohort 2 as of the DCO:

• Of these 25 patients, 20 (80%) remained progression-free. Eight patients had achieved confirmed responses per investigator-assessed RECIST v1.1, all of which occurred in Cohort 2.
• All 23 patients in Cohort 2 had at least one tumor expressing SSTR2, and 16 showed SSTR2 expression in all of their tumors.
• Among the 16 patients with SSTR2 expression in all of their tumors, seven (44%) achieved confirmed responses, and 14 (87.5%) remained progression-free and on study, with a median follow-up of 41 weeks.
  
  

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company’s plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson

PerspectiveIR@russopr.com

FAQ

What did Perspective Therapeutics (CATX) announce about [212Pb]VMT-α-NET for ASCO-GI 2026?

Updated data on [212Pb]VMT-α-NET were accepted for a poster presentation at ASCO-GI Congress 2026.

When and where will Perspective's CATX poster on [212Pb]VMT-α-NET be presented at ASCO-GI 2026?

The poster (Abstract No. 635) will be presented on January 9, 2026 in San Francisco during two poster session times: 11:30 am–1:00 pm PT and 5:00–6:00 pm PT.

Who is presenting Perspective Therapeutics' CATX [212Pb]VMT-α-NET data at ASCO-GI 2026?

Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center is listed as the presenter for Abstract No. 635.

What is the focus of the CATX Abstract No. 635 poster at ASCO-GI 2026?

The poster covers safety and preliminary efficacy results of [212Pb]VMT-α-NET in advanced SSTR2-expressing neuroendocrine tumors.

When will ASCO-GI release full details for regular abstracts for the January 2026 conference?

ASCO-GI will release further details for regular abstracts on January 5, 2026.

Which session will include the Perspective Therapeutics (CATX) poster at ASCO-GI 2026?

The poster is in the session titled Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.